Excedrin QuickTabs launch delay
This article was originally published in The Tan Sheet
Executive Summary
Supplier manufacturing problems continue to postpone launch of Bristol-Myers Squibb's first "melt-in-your-mouth" pain reliever, firm says. Bristol is devising interim marketing plans for other Excedrin products, redesigning QuickTabs launch campaign. Current Excedrin ad agency Bozell Worldwide (New York) will handle QuickTabs market introduction. Product, which contains 500 mg acetaminophen, 65 mg caffeine, will be priced similarly with Excedrin Aspirin-Free and will come in 16- and 32-count sizes...
You may also be interested in...
Excedrin Quick Tabs Will Be On OTC Shelves By Labor Day
Bristol-Myers Squibb will back the upcoming launch of Excedrin Quick Tabs with a six-month, $20 mil. advertising/marketing campaign, the firm said at the National Association of Chain Drug Stores Marketplace Conference in San Diego, Calif. June 15-18
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.